Cell News and Research

RSS

DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns

The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.

23 Nov 2010

Researcher develops new method that causes cancer cells to self-destruct

Tulane University researcher W T. Godbey has developed a treatment for cancer using a method that causes cancer cells to self-destruct while sparing surrounding healthy cells.

23 Nov 2010

Breakthrough with mutant gene that causes familial ALS

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that eventually destroys most motor neurons, causing muscle weakness and atrophy throughout the body. There is no cure and the current treatment has only a moderate effect on the march of the disease, which typically kills within three to five years. This week in PNAS, a team of Brandeis scientists reports an innovative approach to treating the most common form of familial ALS, commonly known as Lou Gehrig's disease.

23 Nov 2010

New computer method measures mechanical stress in fat cells

From fad diets to exercise programs, Americans continue to fight the battle of the bulge. Now they'll have help from recent Tel Aviv University research that has developed a new method to look at how fat cells which produce the fat in our bodies respond to mechanical loads.

23 Nov 2010

Compugen announces development of Protein Family Members Discovery Platform

Compugen Ltd. announced today the development of its Protein Family Members Discovery Platform, designed for the discovery of novel protein members belonging to various known and clinically important protein families.

23 Nov 2010

HIV drugs lead to insulin resistance

The same powerful drugs that have extended the lives of countless people with HIV come with a price - insulin resistance that can lead to diabetes and cardiovascular disease.

23 Nov 2010

Rate, direction of axon growth in spinal cord can be controlled, study shows

Both the rate and direction of axon growth in the spinal cord can be controlled, according to new research by USC College's Samantha Butler and her collaborators.

23 Nov 2010

Different digestive tract bacteria helps infants digest milk more effectively than adults

Infants are more efficient at digesting and utilizing nutritional components of milk than adults due to a difference in the strains of bacteria that dominate their digestive tracts. Researchers from the University of California, Davis, and Utah State University report on genomic analysis of these strains in the November 2010 issue of the journal Applied and Environmental Microbiology identifying the genes that are most likely responsible for this difference.

23 Nov 2010

Grant adds PTR-35 360° vertical rotator to bio product range

Grant Instruments, a world-renowned supplier of scientific, life sciences and data acquisition products, has introduced a variable speed, variable angle 360º vertical rotator combining three mixing functions - vertical rotation, reciprocation and vibration - into one easy-to-use and highly versatile compact unit.

23 Nov 2010

BioCancell raises $5.1 million by excess demand in public offering

Success for BioCancell Therapeutics Inc. Excess demand in BioCancell's public offering of shares and warrants generated immediate proceeds of $5.1 million, 18% above its stated minimal fundraising goal of $4.3 million.

23 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

Transparent develops new medium for Cell-able array kit to maintain metabolite activity

Transparent Inc. announced that it has developed a more advanced medium for Cell-able, a human hepatocyte array kit that has the potential to reduce drug development costs and time-to-market for pharmaceutical companies. Transparent first introduced Cell-able in the United States a year ago.

22 Nov 2010

State roundup: Calif. stem cell research; Mass. prisons change HIV medicine procedure; Native Americans' high suicide rates

When millionaire Silicon Valley real estate developer Bob Klein launched his ballot drive to create a $3-billion state fund for stem-cell research in 2004, he pitched it as a way of taking politics out of science and focusing on cures.

22 Nov 2010

Stem cell trial for eye disease receives FDA approval

The second clinical trial involving stem cells from human embryonic cells has received the go-ahead. The news came from Advanced Cell Technology Inc. this Monday. The company announced that the U.S. Food and Drug Administration has cleared the way for its Phase I/II trial of retinal cells for patients with Stargardt’s macular dystrophy, a childhood version of macular degeneration.

22 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Bacterin secures $8 million financing from WTI

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has secured an asset based lending facility of up to $8.0 million from Western Technology Investment, and has received approximately $980,000 through the exercise of warrants for a total of approximately $9 million potentially available for the Company's use.

22 Nov 2010

First Edition: November 22, 2010

Today's headlines offer a range of health policy stories, including more reports on deficit reduction issues, the continuing politics swirling around the health law repeal effort and employers' soaring health care costs.

22 Nov 2010

SESCAM selects WeatherBug weather monitoring solution for emergency services operations

WeatherBug®, the leading provider of consumer and professional weather products and services and operator of the largest weather observing and lightning network, announced its selection by SESCAM (Servicio de Salud de Castilla-La Mancha), a regional healthcare organization in central Spain that serves more than two million living throughout the region of Castilla-La Mancha.

22 Nov 2010